The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma

Summary

We studied the mode of action of the low molecular weight heparin PK10169 and two of its constituent fractions: EMT 966 High Molecular Weight Fraction and EMT 967 Low Molecular Weight Fraction.

EMT 966 like standard heparin, acts primarily on thrombin formed and not on prothrombinase (S type heparin). In contrast EMT 967 has no direct effect on thrombin. At high concentrations, it inhibits the prothrombinase complex (P type heparin). PK10169, that contains the two EMTs shows both activities: anti thrombin and antiprothrombinase (mixed type heparin).

The addition of increasing amounts of EMT 967 to a constant amount of EMT 966 does not influence the breakdown constant of endogenous thrombin which is determined by the concentration of EMT 966 only. This demonstrates the absence of competition for AT III between the two components of PK10169.

In platelet rich plasma, EMT 966 inhibits and postpones thrombin generation more efficiently than unfractionated heparin, probably because it is less sensitive to neutralization by platelet components (platelet factor 4). Amounts of EMT 967 that hardly inhibit thrombin generation in platelet rich plasma enhance the effect of EMT 966 probably by neutralizing platelet factor 4.

Key words

Low molecular weight heparin - Thrombin - Prothrombin

• References

• 1 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 2 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis 1987. XIth Congress on Thrombosis and Haemostasis; Brussels: 1987. Vermylen J, Lijnen R, Arnout J. (eds) pp 17-36
• 3 Béguin S, Lindhout Th, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 4 Vinazzer H, Woler M. A new low molecular weight heparin fragment (PK10169). In vitro and in vivo studies Haemostasis 1986; 16: 106-115
• 5 Thaler E, Schmer G. A simple two stop isolation procedure for human and bovine antithrombin II/III (heparin co-factor): a comparison of two methods. Br J Haematol 1975; 31: 233-243
• 6 Miller-Andersson M, Borg H, Andersson L-O. Purification of antithrombin III affinity chromatography. Thromb Res 1974; 439-452
• 7 Béguin S, Hemker HC, Lindhout Th. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemostas 1989; 61: 25-9
• 8 Walz DA, Ciaglowski RE, Walenga JM, Fareed J. Studies of the binding of heparin, its low molecular weight fraction and biologically active fragments with bovine and human platelet factor 4. Thromb Haemostas 1983; 50: 183 (Abstr 0563)
• 9 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 10 Walz DA, Hung GL. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Semin Thromb Haemostas 1985; 11: 40-47
• 11 Cowan SW, Bakshi EN, Machin KJ, Isaacs NW. Binding of heparin to human platelet factor 4. Biochem J 1986; 234: 485-488
• 12 Lane DA, Pejler GH, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986
• 13 Bara L, Samama M. The need for standardization of low molecular weight heparin (LMWH). Thromb Haemostas 1986; 56: 418